Progressive Familial Intrahepatic Cholestasis Market to Observe Stupendous Growth During the Forecast Period (2023-32) – DelveInsight | Vivet Therapeutics (VTX-803), Mirum Pharmaceuticals (Maralixibat)

Progressive Familial Intrahepatic Cholestasis Market to Observe Stupendous Growth During the Forecast Period (2023-32) - DelveInsight | Vivet Therapeutics (VTX-803), Mirum Pharmaceuticals (Maralixibat)
Delveinsight Business Research LLP
As per DelveInsight, the Progressive Familial Intrahepatic Cholestasis (PFIC) Market is anticipated to evolve immensely in the coming years owing to the launch of the potential upcoming therapies along with current treatment regimens in the 7MM and the rise in the number of cases.

DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Progressive Familial Intrahepatic Cholestasis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Progressive Familial Intrahepatic Cholestasis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Progressive Familial Intrahepatic Cholestasis Market

Progressive Familial Intrahepatic Cholestasis (PFIC): An Overview

According to the National Institute of Health (NIH), (PFIC) is a heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Key Facts

  • As per the Children’s Liver Disease Foundation, PFIC affects

  • According to Progressive Familial Intrahepatic Cholestasis (PFIC) Organization, mortality rates reported in previous studies ranges from 0-87%. The high number (87%) is probably the mortality rate when PFIC is not treated. Causes of death include infections, liver failure, and complications related to liver transplants.

  • As per a study conducted by Gunaydin et al. [2018], stated that PFICs were responsible for about 10–15% of children with cholestatic liver diseases with the total number of cases from the two subtype prevalent populations (PFIC1 and PFIC2) reported less than 200. PFIC-3 subtype incident population was even rarer, with a reported case number of less than 20.

Progressive Familial Intrahepatic Cholestasis (PFIC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Progressive Familial Intrahepatic Cholestasis pipeline therapies. It also thoroughly assesses the Progressive Familial Intrahepatic Cholestasis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Progressive Familial Intrahepatic Cholestasis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Progressive Familial Intrahepatic Cholestasis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Progressive Familial Intrahepatic Cholestasis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Progressive Familial Intrahepatic Cholestasis Epidemiology, Segmented as –

  • Prevalent Population of PFIC in the 7MM [2019-2032]

  • Diagnosed and Treatable Cases of PFIC in the 7MM [2019–2032]

  • Type-specific Prevalence of PFIC in the 7MM [2019–2032]

Progressive Familial Intrahepatic Cholestasis (PFIC) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis market or expected to be launched during the study period. The analysis covers the Progressive Familial Intrahepatic Cholestasis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Progressive Familial Intrahepatic Cholestasis drugs based on their sale and market share.

The report also covers the Progressive Familial Intrahepatic Cholestasis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Progressive Familial Intrahepatic Cholestasis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Progressive Familial Intrahepatic Cholestasis (PFIC) Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

Progressive Familial Intrahepatic Cholestasis Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Currently, Mirum Pharmaceuticals is leading the therapeutics market with its PFIC drug candidates in the most advanced stage of clinical development.

Progressive Familial Intrahepatic Cholestasis (PFIC) Companies Actively Working in the Therapeutics Market Include

  • Mirum Pharmaceuticals

  • Vivet Therapeutics

And Many Others

Emerging and Marketed Progressive Familial Intrahepatic Cholestasis (PFIC) Therapies Covered in the Report Include:

  • VTX-803: Vivet Therapeutics

  • Maralixibat: Mirum Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Progressive Familial Intrahepatic Cholestasis Competitive Intelligence Analysis

4. Progressive Familial Intrahepatic Cholestasis Market Overview at a Glance

5. Progressive Familial Intrahepatic Cholestasis Disease Background and Overview

6. Progressive Familial Intrahepatic Cholestasis Patient Journey

7. Progressive Familial Intrahepatic Cholestasis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Progressive Familial Intrahepatic Cholestasis Treatment Algorithm, Current Treatment, and Medical Practices

9. Progressive Familial Intrahepatic Cholestasis Unmet Needs

10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis Treatment

11. Progressive Familial Intrahepatic Cholestasis Marketed Therapies

12. Progressive Familial Intrahepatic Cholestasis Emerging Drugs and Latest Therapeutic Advances

13. Progressive Familial Intrahepatic Cholestasis Seven Major Market Analysis

14. Attribute Analysis

15. Progressive Familial Intrahepatic Cholestasis Market Outlook (In US, EU5, and Japan)

16. Progressive Familial Intrahepatic Cholestasis Companies Active in the Market

17. Progressive Familial Intrahepatic Cholestasis Access and Reimbursement Overview

18. KOL Views on the Progressive Familial Intrahepatic Cholestasis Market

19. Progressive Familial Intrahepatic Cholestasis Market Drivers

20. Progressive Familial Intrahepatic Cholestasis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight 

Artificial Cornea and Corneal Implant Market

“Artificial Cornea and Corneal Implant Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Artificial Cornea and Corneal Implant market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Artificial Cornea and Corneal Implant Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: